Hodogaya Chemical Co., Ltd.
4112・Prime Market・Chemicals
Business
Hodogaya Chemical Co., Ltd. is a specialty chemicals manufacturer founded in 1916, operating five segments: Functional Dyes, Functional Resins, Basic Chemicals, Agroscience, and Logistics-Related. The core Functional Dyes segment accounts for approximately 54% of consolidated net sales, centered on Organic EL Materials (for smartphones and tablets), and also encompasses dyes, Imaging Materials, and Bio Materials. The company is characterized by technological integration with light-emitting materials through SFC CO., LTD. of Korea, and global expansion leveraging its network of sales and manufacturing bases across Europe, the US, and Asia. Its major customer base includes Samsung Display Co., LTD. (32.4% of net sales), and the company is listed on the Prime Market of the Tokyo Stock Exchange.
Business Model
A manufacturing-and-sales model built on organic synthesis technology, whereby specialty chemicals are produced at company and group factories and supplied to customers through domestic and overseas sales subsidiaries and distributor networks. The Functional Dyes segment accounts for the majority of profit, with continued investment of ¥5,924 million in R&D expenses (FY2026 (ending March 2026)) to maintain differentiation in high-performance materials. In-house handling of hazardous materials transport and storage through logistics subsidiaries improves group efficiency and secures stable cash flow (operating CF of ¥6,092 million).
Company Strengths
The company possesses an integrated development system combining its own hole transport, electron transport, and surface protection materials with the light-emitting materials of South Korea's SFC CO., LTD. Sales to Samsung Display Co., LTD. reached ¥15,556 million (32.4% of consolidated net sales), reflecting a long-term trading relationship. Close, collaborative development leveraging the Tsukuba Research Laboratory and the Korea Research Laboratory is a source of competitive advantage.
As of the end of FY2026 (ending March 2026), the equity ratio stood at 60.8% and total net assets were ¥63,613 million, indicating high financial soundness. Free cash flow was ¥1,065 million (an improvement of ¥1,944 million year on year), and the company achieved five consecutive years of dividend increases while funding capital expenditure of ¥5,084 million for functional dyes primarily with internal funds.
In addition to three domestic plants (Yokohama, Koriyama, and Nanyo), the company operates manufacturing and sales sites in South Korea, the United States, Europe, China, and Taiwan. In March 2026, the company decided to make Hungary's Framochem a wholly owned subsidiary, establishing a global supply system for phosgene derivatives. Manufacturing and logistics know-how for hazardous materials and toxic substances constitutes a unique asset that is difficult for competitors to replicate in a short period.
ENVALITH's Perspective
Performance Trend
Revenue grew from ¥41,879 million in FY2022 to ¥48,578 million in FY2025, but FY2026 saw the first decline, coming in at ¥48,040 million (down 1.1% year on year). Operating profit deteriorated significantly, falling 23.9% from ¥4,875 million to ¥3,711 million, with the operating margin declining from 10.0% to 7.7%. As an external factor, rising raw material and fuel prices and increased logistics costs stemming from the situation in the Middle East pressured profitability. Meanwhile, net income increased year on year to ¥4,706 million, benefiting from adjustments to income taxes (¥-1,039 million), while net income attributable to owners of the parent came to only ¥3,054 million (down 3.9% year on year). Comprehensive income improved substantially to ¥6,333 million (up 230.2% year on year), as improvements in the foreign currency translation adjustment and valuation difference on available-for-sale securities pushed up net assets.
Growth Strategy
Under the new medium-term management plan 'Code 2030', the company aims to accelerate growth through deepening the Organic EL Materials business and the consolidation of Framochem
While maintaining a stable supply system for Organic EL Materials for smartphones and tablets, the company continues to develop next-generation light-emitting and transport materials. It is leveraging its local development and manufacturing setup in South Korea through SFC CO.,LTD. to strengthen close engagement with key customers. In FY2026 (ending March 2026), demand was maintained at a level similar to the previous fiscal year.
Framochem will become a consolidated subsidiary from FY2027 (ending March 2027), and is expected to contribute to net sales. It is positioned as a key driver of the projected increase in net sales for FY2027 (ending March 2027) of ¥52,000 million (an increase of approximately ¥4,000 million year on year), although one-time expenses associated with the acquisition are expected to weigh on profit.
Materials for PCR diagnostic kits and materials for health functional foods (Bio Materials) continued to perform steadily in FY2026 (ending March 2026). The company is investing ¥5,924 million in R&D expenses to advance new themes such as oligonucleic acids for nucleic acid drug raw materials and perovskite-type solar cell materials. Transitioning these to the commercialization phase is key to medium-term profit growth.
Turning around the Functional Resins segment, which posted an expanded operating loss of ¥589 million in FY2026 (ending March 2026), is an urgent priority. The company aims to restore profitability through improved supply capacity following the completion of ODI production capacity expansion in the Specialty Chemicals business, expanded adoption of the new polyol (PTG-SOFTENA), and increased sales of new products in the Building Materials business.
Last updated: July 19, 2026